Xeris Pharmaceuticals Inc traded at $1.56 this Friday December 2nd, increasing $0.01 or 0.65 percent since the previous trading session. Looking back, over the last four weeks, Xeris Pharmaceuticals Inc gained 1.96 percent. Over the last 12 months, its price fell by 23.53 percent. Looking ahead, we forecast Xeris Pharmaceuticals Inc to be priced at 1.35 by the end of this quarter and at 1.23 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
1.56
Daily Change
0.65%
Yearly
-23.53%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AcelRx Pharmaceuticals 2.24 0.05 2.28% 288.21%
Acura Pharmaceuticals 0.05 0 0% -90.10%
Endo International 0.09 0.001 1.28% -98.10%
Horizon Pharma 104.85 3.97 3.94% 5.02%
Jazz Pharmaceuticals 157.25 0.71 0.45% 30.76%
Eli Lilly 374.76 4.43 1.20% 52.60%
Nektar Therapeutics 3.05 0.17 5.90% -71.84%
Pacira 47.25 0.02 0.04% -10.05%
Perrigo 31.94 -0.20 -0.62% -10.76%
Supernus Pharmaceuticals 37.51 0.49 1.32% 23.43%
Teva Pharmaceutical Industries 8.66 -0.04 -0.46% 7.58%


Xeris Pharmaceuticals Inc
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The Company has two products, Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and Keveyis, a therapy for primary periodic paralysis. The Company uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products. The XeriSol formulation technology is suited for peptides and small molecules that encounter formulation challenges. The XeriJect formulation technology is suited for drugs and biologics consisting of large molecules such as proteins, monoclonal antibodies, and vaccines.